Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

twindemic

- PMLiVE

Roche’s Xofluza issued FDA approval to treat influenza in children aged five years and older

It is the first and only single-dose oral medicine for this indication in children as young as five

- PMLiVE

JCVI publishes statement on London polio vaccination strategy

A total of 116 cases of the virus has been found in London’s wastewater since February

- PMLiVE

GSK to supply 85 million doses of pandemic influenza vaccine to EU

The company has signed a contract for the reservation of future production and supply of its pandemic influenza vaccine, Adjupanrix, to support pandemic preparedness in Europe

- PMLiVE

Over 47,000 stroke patients to miss out on ‘game-changing’ treatment, the Stroke Association warns

This year, NHS England failed to reach its original target to make mechanical thrombectomy available to all suitable patients

- PMLiVE

Shionogi Europe and NHS England agree on antibiotic subscription model

The antibiotic Fetcroja, along with Zavicefta, will be made available as an option to help address antimicrobial resistance

- PMLiVE

NHS England launches pilot programme for high street pharmacy referrals

The scheme aims to diagnose more early stage cancers without the need for a GP appointment

- PMLiVE

UK government allocates up to £680m a year to two funds offering cutting-edge treatments

The new Innovative Medicines Fund will enable patients in England to gain fast-track access to drug treatments

- PMLiVE

Six million patients affected by delay to NHS England’s plans to address COVID-19 backlog

UK’s health and social care secretary Sajid Javid said that the number of patients on these hospital waiting lists would increase before beginning to fall

- PMLiVE

New drug available on NHS will benefit lung cancer patients

Over 850 patients in England diagnosed with NSCLC will be able to access the treatment in year one, with numbers tipped to rise to more than 1,000 patients in year...

- PMLiVE

NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments

The proposed Innovative Medicines Fund is an extension of the existing Cancer Drugs Fund

- PMLiVE

First NHS patient treated with Novartis’ SMA gene therapy Zolgensma

Novartis and NHS England reached a landmark deal for the gene therapy earlier this year

- PMLiVE

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links